StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$172.67+10.49 (+6.47%)

Close on Nov 18, 2026Market cap $11.04BP/E –Yield –

Repligen pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Repligen's pe ratio was 234.5× on Nov 11, 2026, against 889.8× a year earlier. Over the last 5 years it ranged from 45.3× to 889.8×, with a median of 136.4×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026234.5×−557.1
2024Oct 31, 2024791.6×+692.1
2023Dec 29, 202399.5×+43.0
2022Dec 30, 202256.5×−69.6
2021Dec 31, 2021126.1×−107.6
2020Dec 31, 2020233.7×+44.9
2019Dec 31, 2019188.8×+85.4
2018Dec 31, 2018103.4×+41.9
2017Dec 29, 201761.5×−92.6
2016Dec 30, 2016154.1×+49.3
2015Dec 31, 2015104.8×+49.8
2014Dec 31, 201455.0×–

More Repligen figures

See a number that looks wrong?